Frost & Sullivan Predicts Growth for the European Vaccines Market

Frost & Sullivan Predicts Growth for the European Vaccines Market PR Newswire LONDON, Sept. 11, 2012 - Technology innovation and increasing focus on new vaccine development are likely to revolutionise the vaccine industry from prophylactic to therapeutic vaccines LONDON, Sept. 11, 2012 /PRNewswire/ -- As vaccine manufacturers increasingly tend to leverage on novel technologies, and potential late-stage vaccine candidates progress the pipeline and reach the commercialization stage, the European vaccines market is expected to witness significant growth rates. Next generation vaccines such as edible plant-based vaccines could also have a significant impact on vaccines development. New analysis from Frost & Sullivan, Analysis of the European Vaccines Market, (www.pharma.frost.com), finds that the European vaccines market earned revenues of $6.36 billion in 2011 and estimates this to reach $12.05 billion in 2018 at a compound annual growth rate (CAGR) of 9.6% from 2011- 2018. The high levels of unmet medical needs for diseases such as AIDS, malaria and tuberculosis - which affect millions of people every year and contribute to increasing healthcare expenditure - present huge growth potential and untapped market opportunities, thereby fuelling increased R&D investments and government support for vaccine development.